The pharmacology of the novel and selective sigma ligand, PD 144418

Neuropharmacology

Volumn 36, Issue 1, 1997, Pages 51-62

  Akunne, H C ^a   Whetzel, S Z ^a   Wiley, J N ^a   Corbin, A E ^a   Ninteman, F W ^a   Tecle, H ^a   Pei, Y ^a   Pugsley, T A ^a   Heffner, T G ^a  

^a PFIZER INC   (United States)

Author keywords

benzomorphan; guinea pig brain; radioligand binding; sigma sites

Indexed keywords

5 HYDROXYTRYPTOPHAN; CYCLIC GMP; HALOPERIDOL; MESCALINE; PD 144418; RECEPTOR SUBTYPE; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL CULTURE; CEREBELLUM; CONTROLLED STUDY; GUINEA PIG; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CALCIUM; CELLS, CULTURED; CYCLIC GMP; GUINEA PIGS; HALOPERIDOL; ISOXAZOLES; MALE; MICE; MOTOR ACTIVITY; N-METHYLASPARTATE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, SIGMA;

EID: 0031056396     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00161-X     Document Type: Article

References (50)

1. αMeArg-Lys-Pro-Trptleu-Leu {NT1}. Biochem. Pharmacol. 49:1995;1147-1154.
2. Beart P.M., O'Shea R.D., Manallack D.T. Regulation of σ-receptors: high- and low-affinity agonist states, GTP shifts, and up-regulation by rimcazole and 1,3-di(2-toly)guanidine. J. Neurochem. 53:1989;779-788.
3. Bredt S.S., Snyder S.H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. natn. Acad. Sci. U.S.A. 86:1989;9030-9033.
4. Brent P.J., Saunders H., Dunkley P.R. Intrasynaptosomal free calcium levels in rat forebrain synaptosomes:modulation by sigma (σ) receptor ligands. Neurosci. Lett. 211:1996;138-142.
5. Campbell B.G., Scherz M.W., Keana J.F.W., Weber E. Sigma receptors inhibit contractions of the guinea pig ileum longitudinal muscle/myenteric plexus preparation elicited by both electrical stimulation and exogenous serotonin. J. Neurosci. 9:1989;3380-3391.
6. 1 binding sites in guinea pig brain. Eur. J. Pharmacol. 251:1994;R1-R2.
7. Chio C.L., Lajiness M.E., Huff R.M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 45:1993;51-60.
8. 2+ channels in rat and mouse cultured hippocampal pyramidal neurones. Br. J. Pharmacol. 116:1995;2801-2810.
9. Clark D., Engberg G., Pileblad E., Svensson T.H., Carlsson A., Freeman A.S., Bunney B.S. An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system. Naunyn Schmiedeberg's Arch. Pharmacol. 329:1985;344-354.
10. Cook L., Tam S.W., Rohrbach K.W. DUP 734 [1-(cyclopropylmethyl)-4-(2′(4″- fluorophenyl)-2′-oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects. J. Pharmacol. Exp. Ther. 263:1992;1159-1166.
11. 3H]-(+)pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett. 251:1989;53-58.
12. Fellows E.J. and Cook L. (1957) The comparative pharmacology of a number of phenothiazine derivatives. In: Psychotropic Drugs (Garrattivi S. and Ghatti V., Eds), pp. 397-404. Elsevier, Amsterdam.
13. Ferris R.M., Harfenisk M., McKenzie G.M., Cooper B., Soroko F.E., Maxwell B.A. BW 234U, (cis 9-[3-(3,5-dimethyl-1-piperazinyl)propyl] carbazole dihydrochloride; a novel antipsychotic agent. J. Pharm. Pharmacol. 34:1982;388-390.
14. Ferris C.D., Hirsch D.J., Brooks B.P., Snyder S.H. σ Receptors: from molecule to man. J. Neurochem. 57:1991;729-737.
15. Goldstein S.R., Matsumoto R.R., Thompson T.L., Patrick R.L., Bowen W.D., Walker J.M. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse. 4:1989;254-258.
16. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
17. Gundlach A.L., Largent B.L., Snyder S.H. Phencyclidine and sigma opiate receptors in brain: biochemical and autoradiographical differentiation. Eur. J. Pharmacol. 113:1985;465-466.
18. Haertzen C.A. Subjective effects of narcotic antagonists cyclazocine and nalorphine on the addiction research center inventory (ARCI). Psychopharmacologia. 18:1970;366-377.
19. Hellewell S.B., Bowen W.D. A sigma-like binding sites in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor from that of guinea pig brain. Brain Res. 527:1990;244-253.
20. 1 recognition site. Eur. J. Pharmacol. 271:1994;235-236.
21. Itzhak Y. Multiple affinity binding states of the sigma receptor: effect of GTP-binding protein modifying agents. Mol. Pharmacol. 36:1989;512-517.
22. Itzhak Y. and Stein I. (1992) Pharmacological properties of sigma 1 and sigma 2 receptor-sites: allosteric interactions between sigma 1 and monoamine oxidase (MAO) in the brain. In: Multiple Sigma and PCP Receptor Ligands: Mechanism for Neuromodulation and Neuroprotection (Kamenka J.-M. and Domino E.F., Eds), pp. 241-255. NPP Books, Ann Arbor, MI.
23. Iyengar S., Wood P.L., Mick S.J., Dilworth V.M., Gray N.M., Farah J.M., Rao T.S., Contreras P.C. (+)-3-[3-Hydroxyphenyl-N-(1-propyl) piperidine] selectively differentiates effects of sigma ligands on neurochemical pathways modulated by sigma receptors: evidence for subtypes in vivo. Neuropharmacology. 30:1991;915-922.
24. Lundeen J.E. and Gordon J.H. (1986) Computer analysis of binding data. In: Receptor Binding in Drug Research (O'Brien R.A., Ed.), pp. 31-49. Marcel Dekker, New York.
25. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:1976;517-532.
26. Matsumoto R.R., Hemstreet M.K., Lai N.L., Thurkauf A., De Costa B.R., Rice K.C., Hellewell S.B., Bowen W.D., Walker J.M. Drug specificty of pharmacological dystonia. Pharmacol. Biochem. Behav. 36:1990;151-155.
27. Matsumoto R.R., Bowen W.D., Tom M.A., Nhi Vo V., Truong D.D., DeCosta B.R. Characterization of two novel σ receptor ligands: antidystonic effects in rats suggests α receptor antagonism. Eur. J. Pharmacol. 280:1995;301-310.
28. Menkel M., Terry P., Pontecorvo M., Katz J.L., Witkin J.M. Selective σ ligands block stimulant effects of cocaine. Eur. J. Pharmacol. 201:1991;251-252.
29. Munson P.J., Rodbard D. LIGAND: a versatile computerized approach or characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
30. 3 receptor. J. Med. Chem. 37:1994;4109-4117.
31. Owicki J.C., Parce J.W. Biosensors based on the energy metabolism of living cells: the physical chemistry and cell biology of extracellular acidification. Biosensors Bioelectronics. 7:1992;255-272.
32. Patrick S.L., Walker J.M., Perkel J.M., Lockwood M., Patrick R.L. Increases in rat striatal extracellular dopamine and vacuous chewing produced by two σ receptor ligands. Eur. J. Pharmacol. 231:1993;243-249.
33. Pei Y., Tecle H., Moos W.H., Wise L.D., Akunne H.C., Pugsley T.A., Downs D.A., Heffner T.G. Identification of potent and selective sigma ligands: design, synthesis and structure-activity relationship of tetrahydropyridiny-isoxazoline and -isoxazoles as cyclic analogs of PD 128298 and its regioisomers. Soc. Neurosci. Abst. 19:1993;1153.
34. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by κ opiate receptors. Science. 233:1986;774-776.
35. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioral despair in rats: a new model sensitive to anti-depressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
36. Pugsley T.A., Davis M.D., Akunne H.C., Cooke L.W., Whetzel S.Z., MacKenzie R.G., Shih Y.-H., Van Leewuen D.H., DeMattos S.B., Georgic L.M., Caprathe B.W., Wright J.L., Jaen J.C., Wise L.D., Heffner T.G. CI-1007, a dopamine partial agonist and potential anti-psychotic agent. I: Neurochemical effects J. Pharmacol. Exp. Ther. 274:1995;898-911.
37. Pugsley T.A., Shih Y.-H, Meltzer L., Tecle H., Whetzel S., Pei Y. and Heffner T.G. (1992) Evaluation of a series of tetrahydropyridine oximes as high affinity sigma ligands and pharmacological characterization of PD 128298, an apparent selective sigma ligand. In: Multiple Sigma and PCP Receptor Ligands: Mechanism for Neuromodulation and Neuroprotection (Kamenka J.-M. and Domino E.F., Eds), pp. 117-135. NPP Books, Ann Arbor, MI.
38. Quirion R., Chicheportiche R., Contreras P.C., Johnson K.M., Lodge D., Tam S.W., Woods J.H., Zukin S.R. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 10:1987;444-446.
39. Rao T.S., Cler J.A., Emmett M.R., Mick S., Iyengar S., Wood P.L. BMY-14802 antagonizes harmaline- and D-serine-induced increase in mouse cerebellar cyclic GMP: neurochemical evidence for a σ receptor-mediated functional modulation of responses mediated by the N-methyl-D-aspartate receptor complex in vivo. Mol. Pharmacol. 37:1990;978-982.
40. Scatchard G. The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51:1949;660-672.
41. Schoenwald R.D., Barfknecht C.F., Shirolkar S., Xia E. The effects of sigma ligands on protein release from lacrimal acinar cells: a potential agonist/antagonist assay. Life Sci. 15:1995;1275-1285.
42. Tam S.W. Naloxone-inaccessible σ receptor in rat central nervous system. Proc. natn. Acad. Sci. U.S.A. 80:1983;6703-6707.
43. Turner J.T., James-Kracke M.R., Camden J.M. Regulation of the neurotensin receptor and intracellular calcium mobilization in HT 29 cells. J. Pharmacol. Exp. Ther. 253:1989;1049-1056.
44. Vogel J.R., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
45. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., Rice K.C. Sigma receptors: biology and function. Pharmacol. Rev. 42:1990;355-402.
46. 2 receptors in motor function. Eur. J. Pharmacol. 231:1993;61-68.
47. Wu X.-Z., Bell J.A., Spivak C.E., London E.D., Su T.-P. Electrophysiological and binding studies on intact NCB-20 cells suggest presence of a low affinity sigma receptor. J. Pharmacol. Exp. Ther. 257:1991;351-359.
48. 3H]TCP binding to intact primary cultured neuronal cells. Life Sci. 56: PL39-43.
49. Yevich J.P., New J.S., Lobeck W.G., Dextraze P., Bernstein E., Taylor D., Yocca F.D., Wison M.S., Temple D.L. Jr. Synthesis and biological characterization of a-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol and analogues as potential atypical antipsychotic agents. J. Med. Chem. 35:1992;4516-4525.
50. Young G.A., Khazan N. Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Neuropharmacology. 23:1984;1161-1165.